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tory mutation system.Abstract Background: Apelin is an adipokine that was identified to play a role in the control of
glucose homeostasis. Apelin rs2235306 gene polymorphism was linked to insulin resistance and
poor glycemic control.
Aim of the study: To assess the relation of apelin rs2235306 polymorphism with metabolic syn-
drome and its component traits in Egyptian women from Suez Canal area.
Subjects and methods: The study included 100 metabolic syndrome patients and 100 healthy
female subjects. The component traits of metabolic syndrome were determined and the genotypes
of the polymorphisms were assessed using tetra amplification refractory mutation system polymer-
ase chain reaction (T-ARMS-PCR) technique.
Results: There was no significant difference in the allele frequencies between the metabolic syn-
drome and control groups (P = 0.841). There was also no association of the different genotypes of
this polymorphism with any of the component traits of metabolic syndrome.
Conclusion: Apelin rs2235306 polymorphism is not associated with the incidence of metabolic
syndrome in the studied population.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Apelin is derived from a 77 amino-acid prepropeptide that
produces four active isoforms (apelin-12, 13, 17 and 36), each
showing different receptor-binding affinities, from which
(Pyr1)-apelin-13 has the highest abundance and activity [1,2].
Apelin exerts its paracrine function by binding and activating
the apelin receptor (Aplnr or APJ) [3]. Increasing evidence sug-
gests that apelin regulates multiple physiological functions,
including fluid homeostasis, food intake, cell proliferation,
blood pressure regulation, angiogenesis and glucose utilization
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ity, hypertension or cardiovascular diseases [6,7].
Apelin system is widely expressed in various tissues, includ-
ing adipose tissue, brain, heart, lungs and kidneys [7]. Apelin
production in adipose tissue is regulated by factors, such as
fasting and feeding, insulin level [5], hypoxia [8], growth hor-
mone and tumor necrosis factor a levels [9]. Whereas insulin
stimulates adipose tissue apelin expression, apelin inhibits
insulin secretion [5,9].
Interestingly, apelin-13 has been found to have beneficial
effects on high-fat-diet-induced obese mice, improving glucose
tolerance and increasing glucose utilization in normal and
insulin-resistant mice [10]. Furthermore, intraperitoneal
administration of apelin in normal and obese mice for 14 days
reduced body adiposity without altering food intake or insulin,
leptin and triglyceride levels whereas it increased adiponectin
levels [11]. In a well established mice model of type 1 diabetes,
chronic apelin-13 treatment significantly ameliorated pancre-
atic islet mass and insulin production [12].
Considering these physiological actions in the control of
glucose homeostasis, it is tempting to propose a link between
apelin and obesity-associated insulin resistance. Accordingly,
apelin overproduction in the obese might represent a protec-
tive mechanism before the emergence of type 2 diabetes melli-
tus (T2DM) or cardiovascular disease. Thus, apelin becomes a
potential therapeutic target in diabetes and obesity [13].
The human apelin is localized on chromosome Xq25-q26.1
and contains 3 exons, with the coding region spanning exons 1
and 2 [14]. The rs2235306 variant of apelin showed association
with insulin secretion [15], and fasting glucose level [16].
The metabolic syndrome is an aggregation of several meta-
bolic risk factors, including elevated plasma triglyceride (TG),
reduced high density lipoprotein-cholesterol (HDL-C), ele-
vated blood pressure, and raised plasma glucose. This aggrega-
tion is recognized as a multiplex risk factor for atherosclerotic
cardiovascular disease and T2DM [17]. Metabolic risk factors
are more common in obese individuals. For this reason, obes-
ity is commonly included in the clinical definition of metabolic
syndrome [18].
This study aimed to analyze the relation of apelin
rs2235306 single nucleotide polymorphism (SNP) with meta-
bolic syndrome and its component traits in Egyptian women
from Suez Canal area.
2. Subjects and methods
2.1. Study population
A cross-sectional study was conducted on 200 female sub-
jects.They were divided into 100 healthy subjects and 100 met-
abolic syndrome patients. All subjects were Egyptians of the
same ethnic group. Patients were selected from the Outpatient
Clinic of the Ismailia General Hospital. Diagnosis of metabolic
syndrome was done according to the Third Report of the
National Cholesterol Education Program’s Adult Treatment
Panel (ATPIII). Metabolic syndrome is diagnosed by the pres-
ence of any three or more of the following factors: waist cir-
cumference P88 cm in women; fasting blood glucose (FBG)
P100 mg/dL or known diabetes; serum TG P150 mg/dL;
HDL-C <50 mg/dL in women; and blood pressure P130/
85 mmHg or treated hypertension [17].The study groups included non smokers. Subjects suffering
from heart failure, myocardial infarction, diabetes mellitus
type I, any type of cancer, renal failure or chronic liver disease
were excluded. Pregnant or lactating women and those receiv-
ing hormone replacement therapy or contraceptive medica-
tions were also excluded. All participants had regular
menstruation.
The present study was conducted according to the princi-
ples of the Declaration of Helsinki, and all the participants
provided written informed consent following a protocol
approved by the Faculty of Pharmacy, Suez Canal University
Research Ethics Committee. Body mass index (BMI), waist
circumference, and systolic and diastolic blood pressure were
determined for all the subjects.
2.2. Laboratory measurements
Peripheral blood was drawn after a 12 h fast and a portion was
collected with EDTA and used for DNA extraction. The serum
was separated from the remaining portion of the blood sam-
ples and used for assessment of the following parameters:
Glucose homeostasis traits: FBG was measured by the enzy-
matic colorimetric method (Biodiagnostic, Egypt) and fasting
serum insulin was measured by enzyme linked immune sorbent
assay (Monobind). The homeostasis model assessment of insu-
lin resistance (HOMA-IR) [19] and the quantitative insulin
sensitivity check index (QUICKI) [20] were calculated.
Lipid profile: TG, total cholesterol (TC) and HDL-C were
measured by enzymatic colorimetric methods (Biodiagnostic,
Egypt). Low density lipoprotein-cholesterol (LDL-C) was
calculated [21].
2.3. Genomic DNA extraction and genotyping
Genomic DNA was isolated from 300 lL of whole blood col-
lected in EDTA anticoagulated tubes using theWizard genomic
DNA purification kit (Promega, Madison, USA) according to
the manufacturer’s instructions. The apelin rs2235306 SNP
was detected using tetra amplification refractory mutation
system polymerase chain reaction (T-ARMS-PCR). PCR was
performed by using four primers: forward outer primer [50-A
AGTGGTGCAGGGTATCCTTGGGT-30], reverse outer pri-
mer [50-AAGGAGCCAAGGAAGGAACAGAGC-30], for-
ward inner primer (for T allele) [50-CCCCCTGCACACCAT
CTGCTT-30], and reverse inner primer (for C allele) [50-GGG
ACAGGGATCTAGATGCAGGAAG-30] [22].
PCR amplifications were performed in a total volume of
25 lL containing 1 lL genomic DNA (100 ng/lL), l lL of
each primer (10 pmol/lL), 12.5 lL Go Taq Green Master
Mix (2·) (Promega, Madison, USA) and 7.5 lL DNase-free
water.
Thermal cycling conditions were as follows: an initial dena-
turation step at 95 C for 5 min; followed by 35 cycles of dena-
turation at 95 C for 30 s, annealing at 58 C for 30 s and
extension at 72 C for 60 s; and ending with a final extension
at 72 C for 10 min. Thermal cycling was performed in an
Eppendorf Mastercycler machine (Eppendorf, Hamburg,
Germany). PCR products were verified on a 2.0% agarose
gel. The product sizes of apelin rs2235306 polymorphism were
458 bp for two outer primers (control band), 295 bp for C
allele and 208 bp for T allele (Fig. 1).
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Differences in baseline characteristics between metabolic syn-
drome patients and the control group were assessed through
the Student t-test. Student t-test was also used to determine
the relationship between different genotypes and the clinical
parameters in the study population. Genotype and allele fre-
quencies as well as other qualitative variables were analyzed
with the chi-square test. Additionally, the Chi-square test
was used to determine whether the genotype distribution was
consistent with Hardy–Weinberg equilibrium expectations.
Associations of genotypes with the metabolic syndrome com-
ponent traits were analyzed by one way analysis of variance
(ANOVA) test followed by Tukey’s test for multiple compari-
sons. Analysis was performed using SPSS, version 17.0. All
data are presented as means ± standard deviations (SD)
except where otherwise stated. A value of p < 0.05 was consid-
ered statistically significant.
3. Results
The demographic, clinical and biochemical parameters of the
metabolic syndrome patients and their age-matched controlsFigure 1 Detection of apelin rs2235306 polymorphism genotypes by
primers (control band), 295 bp for C allele, and 208 bp for T allele.
Table 1 General and biochemical characteristics of the study popu
Variables Control (n= 100)
Age (years) 39.98 ± 12.13
BMI (kg/m2) 23.10 ± 1.68
Waist circumference (cm) 76.77 ± 8.50
Systolic blood pressure (mmHg) 109.15 ± 9.02
Diastolic blood pressure (mmHg) 72.40 ± 6.98
Glucose homeostasis traits
FBG (mg/dL) 84.26 ± 10.67
Fasting serum insulin (lIU/ml) 8.50 ± 1.11
HOMA-IR 1.80 ± 0.45
QUICKI 0.351 ± 0.016
Lipid profile
TG (mg/dL) 117.54 ± 22.65
TC (mg/dL) 166.85 ± 27.93
HDL-C (mg/dL) 59.06 ± 10.56
LDL-C (mg/dL) 84.37 ± 29.24
Data are presented as mean ± SD. Comparisons were performed by unp
* Significantly different from normal control at p 6 0.05.are summarized in Table 1. In comparison with the control
group, patients showed a significant increase in serum TG,
TC, LDL-C, fasting blood glucose and fasting serum insulin
levels. Patients had a significantly higher insulin resistance
than controls indicated by a significant increase of HOMA-
IR and a significant decrease of QUICKI. On the other hand,
serum HDL-C levels were significantly decreased in the meta-
bolic syndrome patients as compared to the control subjects.
Additionally, BMI, waist circumference, systolic and diastolic
blood pressure were higher in patients than in controls.
The genotype frequencies of apelin rs2235306 polymor-
phism were in accordance with Hardy–Weinberg equilibrium
in the whole study sample (v2 = 2.47, p= 0.116), as well as
in subjects with metabolic syndrome (v2 = 0.53, p = 0.467),
and control subjects (v2 = 2.23, p = 0.135). As shown in
Table 2; apelin rs2235306 polymorphism did not appear to
be associated with the incidence of metabolic syndrome in
the studied groups.
We also investigated the relation of apelin rs2235306 geno-
types with different clinical parameters in the studied popula-
tion. The different genotypes of the polymorphism showed no
association with any of the components of metabolic syn-
drome. These results are summarized in Table 3.agarose gel electrophoresis. Product sizes are 458 bp for two outer
lation.
Metabolic syndrome patients (n= 100) P
38.76 ± 9.72 0.433
32.31 ± 5.55* 0.001
107.12 ± 10.99 * 0.001
139.85 ± 16.85* 0.001
89.75 ± 8.36* 0.001
157.02 ± 55.10* 0.001
15.80 ± 5.58* 0.001
6.91 ± 4.89* 0.001
0.301 ± 0.026* 0.001
202.00 ± 62.41* 0.001
229.55 ± 37.22* 0.001
42.73 ± 5.66* 0.001
142.06 ± 35.11* 0.001
aired Student t-test.
Table 3 The relationship between apelin rs2235306 polymorphism genotypes and different clinical parameters in the study
population.
Variables Carriers of TT (n= 55) Carriers of TC (n= 110) P (TC vs. TT) Carriers of CC (n= 35) P (CC vs. TT)
BMI (kg/m2) 28.45 ± 5.99 27.17 ± 5.75 0.420 28.23 ± 7.57 0.985
Waist circumference (cm) 92.95 ± 17.02 91.24 ± 19.42 0.836 92.60 ± 15.64 0.996
Systolic blood pressure (mmHg) 123.27 ± 19.77 124.82 ± 20.69 0.892 125.43 ± 21.30 0.878
Diastolic blood pressure (mmHg) 81.27 ± 11.39 80.55 ± 11.26 0.924 82.43 ± 13.14 0.890
Glucose homeostasis traits
FBG (mg/dL) 121.78 ± 55.35 119.12 ± 53.20 0.952 123.63 ± 54.78 0.986
Fasting serum insulin (lIU/mL) 12.25 ± 5.55 12.01 ± 5.42 0.961 12.43 ± 5.42 0.988
HOMA-IR 4.43 ± 4.50 4.27 ± 4.27 0.972 4.51 ± 4.23 0.996
QUICKI 0.325 ± 0.033 0.327 ± 0.033 0.971 0.324 ± 0.033 0.978
Lipid profile
TG (mg/dL) 165.24 ± 70.19 157.55 ± 59.21 0.743 158.17 ± 64.67 0.864
TC (mg/dL) 203.44 ± 40.13 194.10 ± 46.73 0.429 202.86 ± 49.08 0.998
HDL-C (mg/dL) 49.91 ± 11.87 51.92 ± 12.17 0.556 49.23 ± 10.18 0.961
LDL-C (mg/dL) 118.40 ± 37.98 107.99 ± 44.46 0.312 121.49 ± 46.30 0.941
Data are presented as mean ± SD. Comparisons were performed by one way ANOVA test followed by the Tukey’s test for multiple
comparison.
Table 2 Allele frequencies and genotype distribution of apelin rs2235306 polymorphism in the control group and metabolic syndrome
patients.
Control n = 100 Metabolic syndrome n= 100 P OR (95%CI)
T allele 109 111
C allele 91 89 0.841a 1.041 (0.702–1.544)
Genotype
TT 26 29
TC 57 53 0.584b 1.200 (0.627–2.294)
CC 17 18 0.920c 1.053 (0.451–2.461)
Comparisons were performed with the Chi-square test; (CI) = confidence interval; OR = odds ratio.
a T vs. C.
b TT vs. TC.
c TT vs. CC.
38 E.T. Mehanna et al.4. Discussion
Metabolic syndrome is a risk factor for coronary artery disease
as well as diabetes, fatty liver and several cancers. The preva-
lence of metabolic syndrome in women appears to be increas-
ing, particularly in those of childbearing age [23]. Metabolic
syndrome is thought to be attributable to genetic predisposing
factors in combination with environmental factors [24]. Several
candidate gene polymorphisms were found to show association
with metabolic syndrome, such as estrogen receptor alpha [25],
tumor necrosis factor alpha [26], angiotensin converting
enzyme [27], fat mass and obesity-associated protein, tran-
scription factor 7-like 2, apolipoprotein A5, apolipoprotein
C3, interleukin 6 and cholesteryl ester transfer protein [28].
In humans, numerous studies have reported changes in
plasma apelin concentrations and variations of apelin and its
receptor expression in different tissues in physiological and
pathological situations [29]. In obese and hyperinsulinemic
subjects, plasma apelin levels as well as adipose tissue expres-
sion are increased [5]. Plasma apelin levels are also raised in
morbidly obese [30] and T2DM subjects [31]. Non-obese
patients with impaired glucose tolerance or with T2DM alsoexhibited higher concentrations of apelin when compared with
control subjects [32]. It was shown that increased plasma ape-
lin concentration in obese and T2DM subjects is positively cor-
related with insulinemia, glycemia and the percentage of
glycated hemoglobin [33]. A decline in apelin levels after
diet-induced weight loss [34] or bariatric surgery [31] in obese
individuals has also been described, showing that the apelin
upregulation can be reversed [35].
The results of this study show that apelin rs2235306 SNP
had no association with increased risk of metabolic syndrome.
We also found no association of the polymorphism genotypes
with any of the components of metabolic syndrome in the stud-
ied population. These results are in accordance with the find-
ings of Hashemi et al. [22] in Iranian population who
indicated no association between the apelin rs2235306 poly-
morphism and metabolic syndrome. However, the mentioned
article suggested that healthy females carrying apelin TC + CC
genotypes have lower HDL-cholesterol in comparison with
those carrying TT, which is not the case in our study.
The findings of the current research also agree with the
results reported by Zhang et al. [36] who found lack of associ-
ation of this polymorphism with the prevalence of hypertension
Apelin rs2235306 and metabolic syndrome 39in Chinese population. However, they counteract with the find-
ings of another study carried out in Egypt in which rs2235306
showed association with post prandial insulin in both normal
and diabetic females [15]. Apelin rs2235306 showed also associ-
ation with fasting plasma glucose levels in Chinese male sub-
jects with normal glucose regulation [16].
In conclusion, our results showed no significant association
between apelin rs2235306 polymorphism and the frequency of
metabolic syndrome or any of its component traits in the study
population. Our findings are limited by the relatively small
sample size. Further studies on larger scales and from different
ethnicities may be required.
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